Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.53 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.53 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710235 | 1.00 | P4HB (0.53) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL20035072 | 1.00 | P4HB (0.53) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL20035071 | 1.00 | P4HB (0.53) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL16710218 | 0.99 | TSHR (0.55) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL20633948 | 0.99 | TSHR (0.55) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL18134222 | 0.93 | TSHR (0.47) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL18134221 | 0.91 | P4HB (0.47) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL16710232 | 0.89 | LMNA (0.63) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL20035054 | 0.88 | P4HB (0.48) | P4HBPDIA4PDIA3TSHRLMNA | |
| SCHEMBL18136387 | 0.88 | P4HB (0.48) | P4HBPDIA4PDIA3TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938562-B2 | Naphthalene derived chromogenic enzyme substrates | GLYCOSYNTH LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| EP-3066209-B1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | GLYCOSYNTH LTD (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20160298167-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | GLYCOSYNTH LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160298167-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | CYP2R1, TDO2, XDH | P4HB 537/4885PDIA4 2590/4885PDIA3 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.